On 4 June 2026, Episurf Medical AB (publ) ("Episurf") issued convertibles in an aggregated nominal amount of SEK 87,509,176 as part of the consideration to be paid for the acquisition of a property portfolio from Mofast AB. Convertibles in a nominal amount of SEK 87,509,176 have, as of the date of this press release, at the request from holders of convertibles, been converted into 1,591,075,927 Class B shares in Episurf at a conversion price of SEK 0.055 per share in accordance with the terms and conditions of the convertibles.
Through the conversion, the number of Class B shares and votes in Episurf increases by 1,591,075,927, corresponding to a dilution effect of approximately 8.90 per cent of the shares and the votes respectively. Through the conversion, the share capital increases by SEK 15,910,759.27.
For further details, please contact:
Jens Andersson, CEO, Episurf Medical
Tel: +46 (0) 768 55 67 02
Email: jens.andersson@episurf.com
The information was submitted for publication, through the agency of the contact person set out above, at 13:05 CEST on 30 October 2026.
About Episurf Medical AB
Episurf Medical is a property company with exposure to a diversified portfolio of property assets. The company's objective is to create value growth through the acquisition and management of Nordic properties. The company also has a medical technology business based on the individualised implant Episealer® and associated surgical instruments, which are used to treat cartilage injuries in joints. Episurf Medical's head office is located in Stockholm, Sweden.